Patterns of Vitamin D, Parathyroid Hormone and c-Terminal Telopeptide of Collagen Type 1 in Caucasian and African Descent HIV-Infected Populations in Central Europe

Noe, Sebastian; Oldenbuettel, Celia; Heldwein, Silke; Jaeger, Hans; Wolf, Eva

doi:10.4081/idr.2017.7265

Cited by 3 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The generalizability of our data is limited by the racial influence on vitamin D and PTH metabolism in PLWH as demonstrated before [21]. This might also be true for other environmental factors such as geographical location.…”

Section: Discussionmentioning

confidence: 78%

Tenofovir Disoproxil Fumarate Is Associated with a Set-Point Variation in the Calcium-Parathyroid Hormone-Vitamin D Axis: Results from a German Cohort

Noe

Heldwein

Wiese

et al. 2018

Advances in Pharmacological Sciences

Self Cite

View full text Add to dashboard Cite

Background Higher levels of parathyroid hormone have been associated with the use of tenofovir disoproxil fumarate (TDF) in people with and without HIV infection. Yet, alterations in calcium levels have never been elucidated in detail. Objective To compare the association of parathyroid hormone with serum calcium levels and other markers of calcium and bone metabolism in people living with HIV on TDF- and non-TDF-containing antiretroviral therapy. Patients and Methods A retrospective single center cohort study in Munich, Germany. Median and interquartile ranges and absolute and relative frequencies were used to describe continuous and categorical variables, respectively. The Mann–Whitney U test and chi2-test were used for comparisons. Multivariate median regression was performed in a stepwise backward approach. Results 1,002 patients were included (786 (78.4%) male; median age 48 (40–55) years). 564 patients (56.3%) had a TDF-containing ART regimen. PTH concentrations were 46.9 (33.0–64.7) pg/mL and 35.2 (26.4–55.4) pg/mL (P=0.001), 43.3 (30.8–59.8) pg/mL and 31.8 (22.3–49.6) pg/mL (P < 0.001), 46.1 (29.5–65.4) pg/mL and 33.4 (22.6–50.1) pg/mL (P < 0.001), and 37.8 (25.3–57.9) pg/mL and 33.8 (20.1–45.3) pg/mL (P=0.012) within the first, second, third, and fourth quartile of corrected calcium levels for patients with and without TDF-containing ART, respectively. In multivariate median regression, PTH concentration was significantly associated with Cacorr. (−32.2 (−49.8 to −14.8); P < 0.001), female sex (5.2 (1.2–9.2); P=0.010), 25(OH)D (−0.4 (−0.5 to −0.3); P < 0.001), and TDF-use (9.2 (6.0–12.5); P < 0.001). Discussion Higher levels of PTH seem to be needed to maintain normal calcium levels in PLWH on TDF-containing ART compared to non-TDF-containing ART. Optimal concentrations for 25-hydroxy vitamin D and calcium might therefore be different in people using TDF than expected from general populations but also people living with HIV with non-TDF-containing antiretroviral therapy. This might require different supplementation strategies but warrants further investigation.

show abstract

Section: Discussionmentioning

confidence: 78%

Tenofovir Disoproxil Fumarate Is Associated with a Set-Point Variation in the Calcium-Parathyroid Hormone-Vitamin D Axis: Results from a German Cohort

Noe

Heldwein

Wiese

et al. 2018

Advances in Pharmacological Sciences

Self Cite

View full text Add to dashboard Cite

show abstract

“…Vitamin D deficiency, defined as serum 25-hydroxyvitamin D (25(OH)D) levels <20 ng/mL, is highly prevalent in general and particularly in people living with HIV (PLWH) [ 1 – 4 ]. Although there is a consensus on the possible benefits of vitamin D supplementation in PLWH, a population that is at increased risk of low bone mineral density (BMD) and osteoporosis [ 5 ], optimal dosing regimens have not been established.…”

Section: Introductionmentioning

confidence: 99%

Monthly or Weekly Supplementation with Cholecalciferol 20,000 IU in People Living with HIV: Results from a Nested Cohort Study

Noe

Moeckel

Schwerdtfeger

et al. 2018

Interdisciplinary Perspectives on Infectious Diseases

Self Cite

View full text Add to dashboard Cite

Background There is still considerable uncertainty in handling vitamin D deficiency in people living with HIV (PLWH), due to a lack of comparative data and the wide range of recommended daily intake. Nondaily supplementation might be preferred in many PLWH, but recommendation on dosing has not been established. We aimed to compare the efficacy of weekly versus monthly supplementation with cholecalciferol 20,000 IU in a group of PLWH with vitamin D deficiency in Western Europe. Study Design Longitudinal, retrospective nested cohort study of PLWH from two large clinical care centers in Munich, Germany. Results Of 307 patients with vitamin D deficiency, 124 patients received vitamin D supplementation (weekly supplementation in 84 (67.7%)). 46.4% and 22.5% of patients achieved 25(OH)D levels ≥30 ng/mL after 12 months of weekly and monthly supplementation with cholecalciferol 20,000 IU, respectively (p=0.011). Dosing interval as well as 25(OH)D baseline levels >15 ng/mL were associated with the normalization of 25(OH)D. Conclusion A higher rate of 25(OH)D level normalization can be achieved via weekly supplementation. For several PLWH, even a weekly dose of cholecalciferol 20,000 IU might not be adequate to maintain 25(OH)D levels >30 ng/mL without an initial “loading” dose. The response to supplementation is poorly predictable at an individual level.

show abstract

Weight-Bearing Physical Activity Influences the Effect of Vitamin D on Bone Turnover Markers in Patients with Intellectual Disability

May

Winters

2019

Southern Medical Journal

View full text Add to dashboard Cite

Patterns of Vitamin D, Parathyroid Hormone and c-Terminal Telopeptide of Collagen Type 1 in Caucasian and African Descent HIV-Infected Populations in Central Europe

Cited by 3 publications

References 30 publications

Tenofovir Disoproxil Fumarate Is Associated with a Set-Point Variation in the Calcium-Parathyroid Hormone-Vitamin D Axis: Results from a German Cohort

Tenofovir Disoproxil Fumarate Is Associated with a Set-Point Variation in the Calcium-Parathyroid Hormone-Vitamin D Axis: Results from a German Cohort

Monthly or Weekly Supplementation with Cholecalciferol 20,000 IU in People Living with HIV: Results from a Nested Cohort Study

Weight-Bearing Physical Activity Influences the Effect of Vitamin D on Bone Turnover Markers in Patients with Intellectual Disability

Contact Info

Product

Resources

About